核苷酸结合寡聚化结构域样受体蛋白3炎症小体在脑卒中后认知障碍中的研究进展

脑卒中后认知障碍(PSCI)是脑卒中患者常见的并发症，严重影响患者的生活质量。目前，PSCI在临床治疗中尚未发现有效的针对性治疗措施。大量研究证实核苷酸结合寡聚化结构域样受体蛋白3(NLRP3)炎症小体的活化在PSCI中起关键作用，且对其进行的许多抑制性治疗显示出了改善认知障碍的功效。为此，本文总结了NLRP3炎症小体的活化和影响因素及其与PSCI的关系，发现在PSCI的细胞和动物模型中，针对NLRP3或其炎症小体成分的抑制措施可以减轻炎性反应和相应的病理特征，从而促进其认知功能的恢复，因此，靶向NLRP3炎症小体可能是PSCI治疗的新趋势。然而到目前为止，尽管许多药物和治疗措施已成功鉴定出能够抑制NLRP3炎症小体的活化，但其在临床中的治疗效果和安全性仍有待进一步验证。

Advances of NLRP3 Inflammasome in Post-stroke Cognitive Impairment

A common complication of stroke patients is post-stroke cognitive impairment (PSCI) , which significantly reduces their quality of life. There are no effective targeted treatment measures currently available for PSCI in clinical practice. A large number of studies have already indicated that the activation of NLRP3 inflammasome plays a crucial role in PSCI, and many inhibitory treatments have been shown to improve cognitive impairment. The purpose of this study was to summarized the activation and modulating factors of NLRP3 inflammatory bodies and the relationship with PSCI. Some studies have been demonstrated that inhibiting NLRP3 or its associated inflammatory body components reduces the inflammatory response, promoting cognitive function recovery in cell and animal models of PSCI. Consequently, targeting NLRP3 inflammatory bodies may be a new trends of dealing with PSCI treatment. Despite the fact that numerous drugs and therapeutic measures have been proved to suppress the activation of NLRP3 inflammatory bodies, their clinical efficacy and safety have not yet been confirmed.